Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?

TY - JOUR

T1 - Checkpoint Inhibitor Pneumonitis

T2 - Too Clinically Serious For Benefit?

AU - Le, Tri

AU - Minna, John D.

AU - Gerber, David E.

N1 - Funding Information: Disclosure: Dr. Minna has received grants from the National Cancer Institute (SPORE in Lung Cancer P50CA70907). Dr. Gerber has a patent pending (PCT/US2018/018594). The remaining author declares no conflict of interest.Funded in part by the University of Texas Lung Cancer Specialized Program of Research Excellence (SPORE) (P50-CA-070907-08S1; to JDM), National Cancer Institute Midcareer Award in Patient-Oriented Research (K24 CA201543-01; to DEG), and an American Cancer Society-Melanoma Research Alliance Team Award (MRAT-18-114-01-LIB; to DEG). Funding Information: Funded in part by the University of Texas Lung Cancer Specialized Program of Research Excellence (SPORE) (P50-CA-070907-08S1; to JDM), National Cancer Institute Midcareer Award in Patient-Oriented Research (K24 CA201543-01; to DEG), and an American Cancer Society- Melanoma Research Alliance Team Award (MRAT-18-114-01-LIB; to DEG).

PY - 2019/3

Y1 - 2019/3

UR - http://www.scopus.com/inward/record.url?scp=85061648976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061648976&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.12.017

DO - 10.1016/j.jtho.2018.12.017

M3 - Editorial

C2 - 30782379

AN - SCOPUS:85061648976

SN - 1556-0864

VL - 14

SP - 332

EP - 335

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 3

ER -